A phase IV, open label, non comparative, multicenter study to evaluate the long term efficacy and safety and tolerability of oral miglustat as a maintenance after a switch form enzyme replacement therapy ERT in adult patients with stable type 1 Gaucher disease - ND A phase IV, open label, non comparative, multicenter study to evaluate the long term efficacy and sa ...
A phase IV, open label, non comparative, multicenter study to evaluate the long term efficacy and safety and tolerability of oral miglustat as a maintenance after a switch form enzyme replacement therapy ERT in adult patients with stable type 1 Gaucher disease - ND A phase IV, open label, non comparative, multicenter study to evaluate the long term efficacy and sa ...
Gaucher disease is the most common of the glycosphingolipids storage disease and has autosomal recessive inheritance. MedDRA version: 6.1;Level: PT;Classification code 10018048 Gaucher disease is the most common of the glycosphingolipids storage disease and has autosomal reces ...
Trade Name: ZAVESCA84CPS100MG INN or Proposed INN: Miglustat